Myelin oligodendrocyte glycoprotein antibodies: How clinically useful are they?

Current Opinion in Neurology

Volumn 30, Issue 3, 2017, Pages 295-301

  Reindl, Markus ^a   Jarius, Sven ^b   Rostasy, Kevin ^c   Berger, Thomas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

Atypical demyelination; Autoantibodies; Myelin oligodendrocyte glycoprotein; Neuromyelitis optica spectrum disorders; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; PROTEIN ANTIBODY; ANTIBODY;

ACUTE DISSEMINATED ENCEPHALOMYELITIS; ANTIBODY BLOOD LEVEL; DEMYELINATING DISEASE; DISEASE COURSE; FUNCTIONAL DISEASE; HUMAN; IMMUNOASSAY; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; OPTIC NEURITIS; RECURRENT DISEASE; REVIEW; IMMUNOLOGY;

ANTIBODIES; DEMYELINATING DISEASES; HUMANS; MULTIPLE SCLEROSIS; MYELIN-OLIGODENDROCYTE GLYCOPROTEIN; NEUROMYELITIS OPTICA;

EID: 85014116117     PISSN: 13507540     EISSN: 14736551     Source Type: Journal    
DOI: 10.1097/WCO.0000000000000446     Document Type: Review

References (55)

1. Hardy TA, Reddel SW, Barnett MH, et al. Atypical inflammatory demyelinating syndromes of the CNS. Lancet Neurol 2016; 15:967-981.
2. Wingerchuk DM, Banwell B, Bennett JL, et al, International Panel for NMO Diagnosis. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85:177-189.
3. Berger T, Reindl M. Antibody biomarkers in CNS demyelinating diseases: a long and winding road. Eur J Neurol 2015; 22:1162-1168.
4. Ramanathan S, Dale RC, Brilot F. Anti-MOG antibody: the history, clinical phenotype, and pathogenicity of a serum biomarker for demyelination. Autoimmun Rev 2016; 15:307-324.
5. Reindl M, Di Pauli F, Rostasy K, et al. The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 2013; 9:455-461.
6. Hohlfeld R, Dornmair K, Meinl E, et al. The search for the target antigens of multiple sclerosis, part 2: CD8+ T cells, B cells, and antibodies in the focus of reverse-translational research. Lancet Neurol 2016; 15:317-331.
7. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. J Neurol Neurosurg Psychiatry 2016; 87:1005-1015.
8. Waters P, Woodhall M, O'Connor KC, et al. MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2:e89.
9. Probstel AK, Dornmair K, Bittner R, et al. Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 2011; 77:580-588.
10. Mader S, Gredler V, Schanda K, et al. Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8:184.
11. McLaughlin KA, Chitnis T, Newcombe J, et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J Immunol 2009; 183:4067-4076.
12. Sepulveda M, Armangue T, Martinez-Hernandez E, et al. Clinical spectrum associated with MOG autoimmunity in adults: significance of sharing rodent MOG epitopes. J Neurol 2016; 263:1349-1360.
13. Hoftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. Plos One 2013; 8:e79083.
14. Mayer MC, Breithaupt C, Reindl M, et al. Distinction and temporal stability of conformational epitopes on myelin oligodendrocyte glycoprotein recognized by patients with different inflammatory central nervous system diseases. J Immunol 2013; 191:3594-3604.
15. Jarius S, Metz I, Konig FB, et al. Screening for MOG-IgG and 27 other antiglial and antineuronal autoantibodies in 'pattern II multiple sclerosis' and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016; 22:1541-1549.
16. Jarius S, Ruprecht K, Kleiter I, et al, in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13:279.
17. Ketelslegers IA, Van Pelt DE, Bryde S, et al. Anti-MOG antibodies plead against MS diagnosis in an Acquired Demyelinating Syndromes cohort. Mult Scler 2015; 21:1513-1520.
18. Fernandez-Carbonell C, Vargas-Lowy D, Musallam A, et al. Clinical and MRI phenotype of children with MOG antibodies. Mult Scler 2016; 22:174-184.
19. Spadaro M, Gerdes LA, Krumbholz M, et al. Autoantibodies to MOG in a distinct subgroup of adult multiple sclerosis. Neurol Neuroimmunol Neuroin-flamm 2016; 3:e257.
20. Reiber H, Peter JB. Cerebrospinal fluid analysis: disease-related data patterns and evaluation programs. J Neurol Sci 2001; 184:101-122.
21. Baumann M, Hennes EM, Schanda K, et al. Children with multiphasic disseminated encephalomyelitis and antibodies to the myelin oligodendrocyte glycoprotein (MOG): extending the spectrum of MOG antibody positive diseases. Mult Scler 2016; 22:1821-1829.
22. Baumann M, Sahin K, Lechner C, et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatry 2015; 86:265-272.
23. Hacohen Y, Absoud M, Deiva K, et al. Myelin oligodendrocyte glycoprotein antibodies are associated with a non-MS course in children. Neurol Neuroimmunol Neuroinflamm 2015; 2:e81.
24. Hacohen Y, Nishimoto Y, Fukami Y, et al. Paediatric brainstem encephalitis associated with glial and neuronal autoantibodies. Dev Med Child Neurol 2016; 58:836-841.
25. Lechner C, Baumann M, Hennes EM, et al. Antibodies to MOG and AQP4 in children with neuromyelitis optica and limited forms of the disease. J Neurol Neurosurg Psychiatry 2016; 87:897-905.
26. Rostasy K, Mader S, Schanda K, et al. Anti-myelin oligodendrocyte glycoprotein antibodies in pediatric patients with optic neuritis. Arch Neurol 2012; 69:752-756.
27. Brilot F, Dale RC, Selter RC, et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 2009; 66:833-842.
28. Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014; e12.
29. Tardieu M, Banwell B, Wolinsky JS, et al. Consensus definitions for pediatric MS and other demyelinating disorders in childhood. Neurology 2016; 87:S8-S11.
30. Kim SM, Woodhall MR, Kim JS, et al. Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS. Neurol Neuroimmunol Neuroinflamm 2015; 2:e163.
31. Piccolo L, Woodhall M, Tackley G, et al. Isolated new onset 'atypical' optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up. J Neurol 2016; 263:370-379.
32. Jarius S, Kleiter I, Ruprecht K, et al, in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 3: brainstem involvement - frequency, presentation and outcome. J Neuroinflammation 2016; 13:281.
33. Jarius S, Ruprecht K, Kleiter I, et al, in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13:280.
34. Pache F, Zimmermann H, Mikolajczak J, et al, in cooperation with the Neuromyelitis Optica Study Group (NEMOS). MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 4: afferent visual system damage after optic neuritis in MOG-IgG-seropositive versus AQP4-IgG-seropositive patients. J Neuroinflammation 2016; 13:282.
35. Sepulveda M, Armangue T, Sola-Valls N, et al. Neuromyelitis optica spectrum disorders: comparison according to the phenotype and serostatus. Neurol Neuroimmunol Neuroinflamm 2016; 3:e225.
36. Havla J, Kumpfel T, Schinner R, et al. Myelin-oligodendrocyte-glycoprotein (MOG) autoantibodies as potential markers of severe optic neuritis and subclinical retinal axonal degeneration. J Neurol 2016; 264:139-151.
37. Akaishi T, Nakashima I, Takeshita T, et al. Different etiologies and prognoses of optic neuritis in demyelinating diseases. J Neuroimmunol 2016; 299: 152-157.
38. Siritho S, Sato DK, Kaneko K, et al. The clinical spectrum associated with myelin oligodendrocyte glycoprotein antibodies (anti-MOG-Ab) in Thai patients. Mult Scler 2016; 22:964-968.
39. Ramanathan S, Prelog K, Barnes EH, et al. Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis. Mult Scler 2016; 22:470-482.
40. van Pelt ED, Wong YY, Ketelslegers IA, et al. Neuromyelitis optica spectrum disorders: comparison of clinical and magnetic resonance imaging characteristics of AQP4-IgG versus MOG-IgG seropositive cases in the Netherlands. Eur J Neurol 2016; 23:580-587.
41. Cobo-Calvo A, Sepulveda M, Bernard-Valnet R, et al. Antibodies to myelin oligodendrocyte glycoprotein in aquaporin 4 antibody seronegative longitudinally extensive transverse myelitis: clinical and prognostic implications. Mult Scler 2016; 22:312-319.
42. Yan Y, Li Y, Fu Y, et al. Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD. Sci China Life Sci 2016; 59:1270-1281.
43. Chalmoukou K, Alexopoulos H, Akrivou S, et al. Anti-MOG antibodies are frequently associated with steroid-sensitive recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 2015; 2:e131.
44. Kitley J, Waters P, Woodhall M, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 2014; 71:276-283.
45. Sato DK, Callegaro D, Lana-Peixoto MA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 2014; 82:474-481.
46. Paty DW, Oger JJ, Kastrukoff LF, et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38:180-185.
47. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69:292-302.
48. Jarius S, Paul F, Franciotta D, et al. Cerebrospinal fluid findings in aquaporin-4 antibody positive neuromyelitis optica: results from 211 lumbar punctures. J Neurol Sci 2011; 306:82-90.
49. Papadopoulos MC, Bennett JL, Verkman AS. Treatment of neuromyelitis optica: state-of-the-art and emerging therapies. Nat Rev Neurol 2014; 10:493-506.
50. Montcuquet A, Collongues N, Papeix C, et al, NOMADMUS study group and the Observatoire Français de la Sclérose en Plaques (OFSEP). Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders. Mult Scler 2016.
51. Jarius S, Ruprecht K, Wildemann B, et al. Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 2012; 9:14.
52. Jurynczyk M, Tackley G, Kong Y, et al. Brain lesion distribution criteria distinguish MS from AQP4-antibody NMOSD and MOG-antibody disease. J Neurol Neurosurg Psychiatry 2017; 88:132-136.
53. Kaneko K, Sato DK, Nakashima I, et al. Myelin injury without astrocytopathy in neuroinflammatory disorders with MOG antibodies. J Neurol Neurosurg Psychiatry 2016; 87:1257-1259.
54. Wang JJ, Jaunmuktane Z, Mummery C, et al. Inflammatory demyelination without astrocyte loss in MOG antibody-positive NMOSD. Neurology 2016; 87:229-231.
55. Di Pauli F, Hoftberger R, Reindl M, et al. Fulminant demyelinating encephalomyelitis: insights from antibody studies and neuropathology. Neurol Neuroimmunol Neuroinflamm 2015; 2:e175.